Skip to main content
Top
Published in: Diabetologia 5/2007

01-05-2007 | Short Communication

Association of glucose levels and glucose variability with mood in type 1 diabetic patients

Authors: N. Hermanns, C. Scheff, B. Kulzer, P. Weyers, P. Pauli, T. Kubiak, T. Haak

Published in: Diabetologia | Issue 5/2007

Login to get access

Abstract

Aims/hypothesis

The aim of this study was to investigate the association of glucose levels and variability of glucose, assessed by continuous glucose monitoring, with mood in type 1 diabetic patients.

Materials and methods

Thirty-six type 1 diabetic patients (77.8% male, age: 31.1 ± 10.0 years; disease duration: 14.7 ± 7.1 years, BMI: 26.7 ± 5.1 kg/m2, HbA1c 8.4 ±1.8%, 27.8% with continuous subcutaneous insulin infusion [CSII] therapy) used a continuous glucose monitoring system for 48.8 h. During this time the patients rated their current mood states 14.6 times on average, using the University of Wales Institute of Science and Technology Mood Adjective Checklist and hand-held computers.

Results

Sensor performance was satisfactory, with a mean absolute difference from reference laboratory glucose measurement of 13.7%. Current glucose values were significantly associated with ratings of ‘tension’ (z = 2.40), ‘hedonic tone’ (z = −2.63) and ‘energetic arousal’ (z = −2.09). ‘Anger’ (z = 1.64) was not significantly associated with glucose values. The glucose AUC during the 60 min prior to the mood rating showed similar associations. The two parameters of glucose variability—coefficient of variation and absolute glucose change during the 60 min prior to the mood ratings—did not show any significant association with the mood ratings. The magnitude of association was significantly higher for glucose level than for glucose variability in the scales ‘tension’ and ‘hedonic tone’.

Conclusions/interpretation

High glucose values had a negative impact on mood; positive mood ratings decreased, whereas negative mood ratings increased. The association between mood and glucose variability seemed to be less important than that between glucose level and mood.
Literature
1.
go back to reference Hermanns N, Kulzer B, Krichbaum M et al (2005) Affective and anxiety disorders in a German sample of diabetic patients: prevalence, comorbidity and risk factors. Diabet Med 22:293–300PubMedCrossRef Hermanns N, Kulzer B, Krichbaum M et al (2005) Affective and anxiety disorders in a German sample of diabetic patients: prevalence, comorbidity and risk factors. Diabet Med 22:293–300PubMedCrossRef
2.
go back to reference Peyrot M, Rubin RR (1997) Levels and risks of depression and anxiety symptomatology among diabetic adults. Diabetes Care 20:585–590PubMedCrossRef Peyrot M, Rubin RR (1997) Levels and risks of depression and anxiety symptomatology among diabetic adults. Diabetes Care 20:585–590PubMedCrossRef
3.
go back to reference Anderson RJ, Freedland KF, Clouse RE et al (2001) The prevalence of comorbid depression in adults with diabetes. Diabetes Care 24:1069–1078PubMedCrossRef Anderson RJ, Freedland KF, Clouse RE et al (2001) The prevalence of comorbid depression in adults with diabetes. Diabetes Care 24:1069–1078PubMedCrossRef
4.
go back to reference Grigsby AB, Anderson RJ, Freedland KE et al (2002) Prevalence of anxiety in adults with diabetes: a systematic review. J Psychosom Res 53:1053–1060PubMedCrossRef Grigsby AB, Anderson RJ, Freedland KE et al (2002) Prevalence of anxiety in adults with diabetes: a systematic review. J Psychosom Res 53:1053–1060PubMedCrossRef
5.
go back to reference Gonder-Frederick LA, Cox DJ, Bobbitt SA et al (1989) Mood changes associated with blood glucose fluctuations in insulin-dependent diabetes mellitus. Health Psychol 8:45–59PubMedCrossRef Gonder-Frederick LA, Cox DJ, Bobbitt SA et al (1989) Mood changes associated with blood glucose fluctuations in insulin-dependent diabetes mellitus. Health Psychol 8:45–59PubMedCrossRef
6.
go back to reference Matthews GM, Jones DM, Chamberlain AG (1990) Refining the measurement of mood: the UWIST Mood Adjective Checklist. Br J Psychol 81:17–42 Matthews GM, Jones DM, Chamberlain AG (1990) Refining the measurement of mood: the UWIST Mood Adjective Checklist. Br J Psychol 81:17–42
7.
go back to reference Hermanns N, Kubiak T, Kulzer B et al (2003) Emotional changes during experimentally induced hypoglycaemia in type 1 diabetes. Biol Psychol 63:15–44PubMedCrossRef Hermanns N, Kubiak T, Kulzer B et al (2003) Emotional changes during experimentally induced hypoglycaemia in type 1 diabetes. Biol Psychol 63:15–44PubMedCrossRef
8.
go back to reference Wentholt IM, Vollebregt MA, Hart AA et al (2005) Comparison of a needle-type and a microdialysis continuous glucose monitor in type 1 diabetic patients. Diabetes Care 28:2871–2876PubMedCrossRef Wentholt IM, Vollebregt MA, Hart AA et al (2005) Comparison of a needle-type and a microdialysis continuous glucose monitor in type 1 diabetic patients. Diabetes Care 28:2871–2876PubMedCrossRef
9.
go back to reference Bode BW, Schwartz S, Stubbs HA et al (2005) Glycemic characteristics in continuously monitored patients with type 1 and type 2 diabetes: normative values. Diabetes Care 28:2361–2366PubMedCrossRef Bode BW, Schwartz S, Stubbs HA et al (2005) Glycemic characteristics in continuously monitored patients with type 1 and type 2 diabetes: normative values. Diabetes Care 28:2361–2366PubMedCrossRef
Metadata
Title
Association of glucose levels and glucose variability with mood in type 1 diabetic patients
Authors
N. Hermanns
C. Scheff
B. Kulzer
P. Weyers
P. Pauli
T. Kubiak
T. Haak
Publication date
01-05-2007
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 5/2007
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-007-0643-y

Other articles of this Issue 5/2007

Diabetologia 5/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.